Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Leukemia
- Sponsor
- Children's Oncology Group
- Enrollment
- 40
- Primary Endpoint
- Reduction in chemotherapy sensitivity by relapsed samples compared to diagnostic samples
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients.
PURPOSE: This research trial is studying proteins that may promote chemotherapy resistance in samples from patients with acute myeloid leukemia.
Detailed Description
OBJECTIVES: * Investigate whether changes in prosurvival signaling occur by comparing activation of the signal transducer and activator of transcription-3 (Stat3) and Stat5 pathways in paired diagnostic and relapse samples. * Investigate changes in leukemia cell responses to extrinsic cues from the environment change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance. OUTLINE: Cryopreserved samples are analyzed for Stat3 and Stat5 expression by flow cytometry and in vitro chemotherapy sensitivity.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Reduction in chemotherapy sensitivity by relapsed samples compared to diagnostic samples
Changes in Stat3 and Stat5 in paired diagnostic and relapsed AML samples